To further elucidate the role of the IRAK4/NF-κB axis in AD, we combined the IRAK4 inhibitor Zimlovisertib and the NF-κB inhibitor QNZ to treat DNFB-induced AD mice by either transdermal drug delivery systems (TDDs) or oral administration (p.o.). The gene discussed is NFKB1; the disease is Alzheimer disease.